Matthias Eiber

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8200963/publications.pdf

Version: 2024-02-01

179	10,705	36203	34900
papers	citations	51 h-index	98 g-index

181	181	181	6545
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Evaluation of Hybrid ⁶⁸Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. Journal of Nuclear Medicine, 2015, 56, 668-674.	2.8	907
2	Diagnostic Efficacy of ⁶⁸ Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. Journal of Urology, 2016, 195, 1436-1443.	0.2	659
3	Current use of PSMAâ€“PET in prostate cancer management. Nature Reviews Urology, 2016, 13, 226-235.	1.9	469
4	Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer. European Urology, 2016, 70, 829-836.	0.9	456
5	⁶⁸Ga- and ¹⁷⁷Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. Journal of Nuclear Medicine, 2015, 56, 1169-1176.	2.8	432
6	18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncology, The, 2019, 20, 1286-1294.	5.1	338
7	Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2114-2121.	3.3	302
8	Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. Radiographics, 2018, 38, 200-217.	1.4	262
9	Value of ⁶⁸Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy. Journal of Nuclear Medicine, 2016, 57, 1713-1719.	2.8	213
10	Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer. European Urology, 2019, 75, 920-926.	0.9	206
11	99mTechnetium-based Prostate-specific Membrane Antigenâ€“radioguided Surgery in Recurrent Prostate Cancer. European Urology, 2019, 75, 659-666.	0.9	195
12	Prostate-specific Membrane Antigenâ€“radioguided Surgery for Metastatic Lymph Nodes in Prostate Cancer. European Urology, 2015, 68, 530-534.	0.9	192
13	E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1626-1638.	3.3	188
14	In vivo molecular imaging of chemokine receptor <scp>CXCR</scp> 4 expression in patients with advanced multiple myeloma. EMBO Molecular Medicine, 2015, 7, 477-487.	3.3	180
15	Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine. Journal of Nuclear Medicine, 2019, 60, 13S-19S.	2.8	172
16	68Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report. Cancer Imaging, 2016, 16, 14.	1.2	171
17	Preclinical Evaluation and First Patient Application of^{99m}Tc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer. Journal of Nuclear Medicine, 2017, 58, 235-242.	2.8	170
18	Systemic Radioligand Therapy with ¹⁷⁷ Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer. Journal of Urology, 2016, 196, 382-391.	0.2	166

#	Article	IF	Citations
19	PSMA Ligands for PET Imaging of Prostate Cancer. Journal of Nuclear Medicine, 2017, 58, 1545-1552.	2.8	165
20	Matched-Pair Comparison of ⁶⁸Ga-PSMA-11 PET/CT and ¹⁸F-PSMA-1007 PET/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical Prostatectomy. Journal of Nuclear Medicine, 2020, 61, 51-57.	2.8	161
21	Radiation Dosimetry for¹⁷⁷Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions. Journal of Nuclear Medicine, 2017, 58, 445-450.	2.8	144
22	Efficacy, Predictive Factors, and Prediction Nomograms for 68 Ga-labeled Prostate-specific Membrane Antigenâ€“ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy. European Urology, 2018, 73, 656-661.	0.9	129
23	Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA. European Urology, 2021, 79, 343-350.	0.9	128
24	Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors. Journal of Experimental Medicine, 2018, 215, 159-175.	4.2	121
25	Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncology, The, 2021, 22, 1115-1125.	5.1	120
26	Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 4377-4385.	3.3	114
27	⁶⁸Ga-PSMA-HBED-CC PET for Differential Diagnosis of Suggestive Lung Lesions in Patients with Prostate Cancer. Journal of Nuclear Medicine, 2016, 57, 367-371.	2.8	112
28	First Experience with Chemokine Receptor CXCR4â€“Targeted PET Imaging of Patients with Solid Cancers. Journal of Nuclear Medicine, 2016, 57, 741-746.	2.8	109
29	Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 602-612.	3.3	107
30	⁶⁸Ga-PSMA-HBED-CC Uptake in Cervical, Celiac, and Sacral Ganglia as an Important Pitfall in Prostate Cancer PET Imaging. Journal of Nuclear Medicine, 2018, 59, 1406-1411.	2.8	106
31	Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1622-1635.	3.3	91
32	Consensus on molecular imaging and theranostics in prostate cancer. Lancet Oncology, The, 2018, 19, e696-e708.	5.1	90
33	⁶⁸Gaâ€PSMAâ€PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment. Prostate, 2017, 77, 920-927.	1.2	89
34	[111In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery. EJNMMI Research, 2015, 5, 68.	1.1	88
35	Value of ¹¹¹Inâ€prostateâ€specific membrane antigen (<scp>PSMA</scp>)â€radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical followâ€up. BJU International, 2017, 120, 40-47.	1.3	88
36	qPSMA: Semiautomatic Software for Whole-Body Tumor Burden Assessment in Prostate Cancer Using ⁶⁸Ga-PSMA11 PET/CT. Journal of Nuclear Medicine, 2019, 60, 1277-1283.	2.8	82

#	Article	IF	Citations
37	Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer. European Urology, 2019, 76, 517-523.	0.9	81
38	Radiohybrid Ligands: A Novel Tracer Concept Exemplified by ¹⁸F- or ⁶⁸Ga-Labeled rhPSMA Inhibitors. Journal of Nuclear Medicine, 2020, 61, 735-742.	2.8	76
39	68Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer. Abdominal Imaging, 2015, 40, 1769-1771.	2.0	74
40	The use of PET/CT in prostate cancer. Prostate Cancer and Prostatic Diseases, 2018, 21, 4-21.	2.0	70
41	Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT). BMC Cancer, 2017, 17, 361.	1.1	67
42	Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 9-15.	3.3	67
43	¹⁸F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. Journal of Nuclear Medicine, 2020, 61, 696-701.	2.8	67
44	Biodistribution and radiation dosimetry of 68Ga-PSMA HBED CCâ€"a PSMA specific probe for PET imaging of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1962-1970.	3.3	66
45	Detection Efficacy of Hybrid ⁶⁸Ga-PSMA Ligand PET/CT in Prostate Cancer Patients with Biochemical Recurrence After Primary Radiation Therapy Defined by Phoenix Criteria. Journal of Nuclear Medicine, 2017, 58, 1081-1087.	2.8	66
46	Deep neural network for automatic characterization of lesions on 68Ga-PSMA-11 PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 603-613.	3.3	66
47	Technologies for image-guided surgery for managing lymphatic metastases in prostate cancer. Nature Reviews Urology, 2019, 16, 159-171.	1.9	62
48	Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer. EJNMMI Research, 2018, 8, 96.	1.1	58
49	One-Stop-Shop Whole-Body ⁶⁸Ga-PSMA-11 PET/MRI Compared with Clinical Nomograms for Preoperative T and N Staging of High-Risk Prostate Cancer. Journal of Nuclear Medicine, 2018, 59, 1850-1856.	2.8	55
50	A machine learning model for the prediction of survival and tumor subtype in pancreatic ductal adenocarcinoma from preoperative diffusion-weighted imaging. European Radiology Experimental, 2019, 3, 41.	1.7	55
51	The Effect of Total Tumor Volume on the Biologically Effective Dose to Tumor and Kidneys for ¹⁷⁷Lu-Labeled PSMA Peptides. Journal of Nuclear Medicine, 2018, 59, 929-933.	2.8	54
52	Discrimination Between Brown and White Adipose Tissue Using a 2-Point Dixon Waterâ€"Fat Separation Method in Simultaneous PET/MRI. Journal of Nuclear Medicine, 2015, 56, 1742-1747.	2.8	45
53	Performance of [68Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomyâ€"a multi-centre evaluation of 2533 patients. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2925-2934.	3.3	43
54	Head-to-Head Comparison of ⁶⁸Ga-PSMA-11 PET/CT and mpMRI with a Histopathology Gold Standard in the Detection, Intraprostatic Localization, and Determination of Local Extension of Primary Prostate Cancer: Results from a Prospective Single-Center Imaging Trial. Journal of Nuclear Medicine, 2022, 63, 847-854.	2.8	43

#	Article	IF	Citations
55	Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography. European Urology, 2022, 82, 156-160.	0.9	43
56	Prospective evaluation of [11C]Choline PET/CT in therapy response assessment of standardized docetaxel first-line chemotherapy in patients with advanced castration refractory prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2105-2113.	3.3	42
57	Tumor Sink Effect in ⁶⁸Ga-PSMA-11 PET: Myth or Reality?. Journal of Nuclear Medicine, 2022, 63, 226-232.	2.8	42
58	Modeling and Predicting Tumor Response in Radioligand Therapy. Journal of Nuclear Medicine, 2019, 60, 65-70.	2.8	41
59	Efficacy and Safety of 177Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study. European Urology, 2020, 78, 148-154.	0.9	39
60	Quantitative and Qualitative Analyses of Biodistribution and PET Image Quality of a Novel Radiohybrid PSMA, ¹⁸F-rhPSMA-7, in Patients with Prostate Cancer. Journal of Nuclear Medicine, 2020, 61, 702-709.	2.8	38
61	Prostate-specific Membrane Antigen PET in Prostate Cancer. Radiology, 2021, 299, 248-260.	3.6	38
62	The added value of PSMA PET/MR radiomics for prostate cancer staging. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 527-538.	3.3	38
63	Imaging for Prostate Cancer Recurrence. European Urology Focus, 2016, 2, 139-150.	1.6	36
64	Matched-Pair Comparison of ⁶⁸Ga-PSMA-11 and ¹⁸F-rhPSMA-7 PET/CT in Patients with Primary and Biochemical Recurrence of Prostate Cancer: Frequency of Nonâ€“Tumor-Related Uptake and Tumor Positivity. Journal of Nuclear Medicine, 2021, 62, 1082-1088.	2.8	36
65	Prospective head-to-head comparison of 11C-choline-PET/MR and 11C-choline-PET/CT for restaging of biochemical recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2179-2188.	3.3	35
66	Histologically Confirmed Diagnostic Efficacy of ¹⁸F-rhPSMA-7 PET for N-Staging of Patients with Primary High-Risk Prostate Cancer. Journal of Nuclear Medicine, 2020, 61, 710-715.	2.8	34
67	Early Prostate-Specific Antigen Changes and Clinical Outcome After ¹⁷⁷Lu-PSMA Radionuclide Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine, 2020, 61, 1476-1483.	2.8	34
68	Prostate-specific Membrane Antigen Positron Emission Tomographyâ€“detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation. European Urology Focus, 2021, 7, 309-316.	1.6	34
69	Exploring New Multimodal Quantitative Imaging Indices for the Assessment of Osseous Tumor Burden in Prostate Cancer Using ⁶⁸Ga-PSMA PET/CT. Journal of Nuclear Medicine, 2017, 58, 1632-1637.	2.8	33
70	Synthesis and preclinical evaluation of novel 18F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with 18F-DCFPyl and 18F-PSMA-1007. EJNMMI Research, 2018, 8, 30.	1.1	33
71	⁶⁸ Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study. Journal of Urology, 2019, 202, 1174-1181.	0.2	33
72	Prostate-Specific Membrane Antigenâ€“Guided Surgery. Journal of Nuclear Medicine, 2020, 61, 6-12.	2.8	31

#	Article	IF	Citations
73	PSMA-PET/CTâ€“based Lymph Node Atlas for Prostate Cancer Patients Recurring After Primary Treatment: Clinical Implications for Salvage Radiation Therapy. European Urology Oncology, 2021, 4, 73-83.	2.6	30
74	Early Experience of Rechallenge ¹⁷⁷Lu-PSMA Radioligand Therapy After an Initial Good Response in Patients with Advanced Prostate Cancer. Journal of Nuclear Medicine, 2019, 60, 644-648.	2.8	29
75	Detection of Circulating Tumor Cells in Locally Advanced High-risk Prostate Cancer During Neoadjuvant Chemotherapy and Radical Prostatectomy. Anticancer Research, 2015, 35, 5679-85.	0.5	29
76	Novel technology of molecular radio-guidance for lymph node dissection in recurrent prostate cancer by PSMA-ligands. World Journal of Urology, 2018, 36, 603-608.	1.2	28
77	The effect of ligand amount, affinity and internalization on PSMA-targeted imaging and therapy: A simulation study using a PBPK model. Scientific Reports, 2019, 9, 20041.	1.6	28
78	Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. Journal of Nuclear Medicine, 2022, , jnumed.121.263072.	2.8	28
79	⁶⁸Ga-PSMA PET/CT and Volumetric Morphology of PET-Positive Lymph Nodes Stratified by Tumor Differentiation of Prostate Cancer. Journal of Nuclear Medicine, 2017, 58, 1949-1955.	2.8	27
80	Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry. EJNMMI Physics, 2020, 7, 41.	1.3	27
81	Evaluation of ¹⁸F-Fluoride PET/MR and PET/CT in Patients with Foot Pain of Unclear Cause. Journal of Nuclear Medicine, 2015, 56, 430-435.	2.8	25
82	11C-choline PET/CT and whole-body MRI including diffusion-weighted imaging for patients with recurrent prostate cancer. Oncotarget, 2017, 8, 66516-66527.	0.8	25
83	Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications. American Journal of Roentgenology, 2018, 211, 286-294.	1.0	25
84	Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer. International Journal of Molecular Sciences, 2021, 22, 7431.	1.8	25
85	Value of diffusion-weighted MR imaging in the diagnosis of lymph node metastases in patients with cholangiocarcinoma. Abdominal Radiology, 2016, 41, 1937-1941.	1.0	24
86	Salvage Surgery in Patients with Local Recurrence After Radical Prostatectomy. European Urology, 2021, 79, 537-544.	0.9	23
87	Whole-body uptake classification and prostate cancer staging in 68Ga-PSMA-11 PET/CT using dual-tracer learning. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 517-526.	3.3	23
88	Visualization of stress fractures of the foot using PET-MRI: a feasibility study. European Journal of Medical Research, 2015, 20, 99.	0.9	22
89	Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer. Journal of Nuclear Medicine, 2021, 62, jnumed.120.256263.	2.8	22
90	Regional Lymph Node Metastasis on Prostate Specific Membrane Antigen Positron Emission Tomography Correlates with Decreased Biochemical Recurrence-Free and Therapy-Free Survival after Radical Prostatectomy: A Retrospective Single-Center Single-Arm Observational Study. Journal of Urology, 2021, 205, 1663-1670.	0.2	22

#	Article	IF	Citations
91	PSMA-Ligand PET for Early Castration-Resistant Prostate Cancer: A Retrospective Single-Center Study. Journal of Nuclear Medicine, 2021, 62, 88-91.	2.8	21
92	Whole-Body [18F]-FDG-PET/MRI for Oncology: A Consensus Recommendation. Nuklearmedizin - NuclearMedicine, 2019, 58, 68-76.	0.3	20
93	Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy. BMC Cancer, 2020, 20, 362.	1.1	20
94	PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study. Journal of Nuclear Medicine, 2022, 63, 76-80.	2.8	20
95	Identification of treatmentâ€induced vulnerabilities in pancreatic cancer patients using functional model systems. EMBO Molecular Medicine, 2022, 14, e14876.	3.3	20
96	PSMA Theranostics Using PET and Subsequent Radioguided Surgery in Recurrent Prostate Cancer. Clinical Genitourinary Cancer, 2016, 14, e549-e552.	0.9	19
97	Can the Injected Dose Be Reduced in 68Ga-PSMA-11 PET/CT While Maintaining High Image Quality for Lesion Detection?. Journal of Nuclear Medicine, 2020, 61, 189-193.	2.8	19
98	Mapping Prostate Cancer Lesions Before and After Unsuccessful Salvage Lymph Node Dissection Using Repeat PSMA PET. Journal of Nuclear Medicine, 2020, 61, 1037-1042.	2.8	19
99	Prostate-specific membrane antigen-guided salvage lymph node dissection in recurrent prostate cancer. Current Opinion in Urology, 2018, 28, 191-196.	0.9	16
100	Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using ¹⁹F/¹⁷⁷Lu-rhPSMA-7.3 and ¹⁷⁷Lu-PSMA I&T. Journal of Nuclear Medicine, 2021, 62, 1106-1111.	2.8	16
101	Identification of PCWG3 Target Populations Is More Accurate and Reproducible with PSMA PET Than with Conventional Imaging: A Multicenter Retrospective Study. Journal of Nuclear Medicine, 2021, 62, 675-678.	2.8	16
102	Automated synthesis of [18F]Ga-rhPSMA-7/ -7.3: results, quality control and experience from more than 200 routine productions. EJNMMI Radiopharmacy and Chemistry, 2021, 6, 4.	1.8	16
103	PSMA PET for the Assessment of Metastatic Hormone-Sensitive Prostate Cancer Volume of Disease. Journal of Nuclear Medicine, 2021, 62, 1747-1750.	2.8	16
104	Value of PET imaging for radiation therapy. Strahlentherapie Und Onkologie, 2021, 197, 1-23.	1.0	16
105	PET/MR in Oncology: Nonâ€“18F-FDG Tracers for Routine Applications. Journal of Nuclear Medicine, 2014, 55, 25S-31S.	2.8	15
106	Whole-Body [18F]-FDG-PET/MRI for Oncology: A Consensus Recommendation. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2019, 191, 289-297.	0.7	15
107	First experiences with Lu-177 PSMA therapy in combination with Pembrolizumab or after pretreatment with Olaparib in single patients. Journal of Nuclear Medicine, 2021, 62, jnumed.120.249029.	2.8	15
108	Utility of ¹⁸F-rhPSMA-7.3 PET for Imaging of Primary Prostate Cancer and Preoperative Efficacy in N-Staging of Unfavorable Intermediate- to Very High-Risk Patients Validated by Histopathology. Journal of Nuclear Medicine, 2022, 63, 1334-1342.	2.8	15

#	Article	IF	Citations
109	From NETTER to PETTER: PSMA-Targeted Radioligand Therapy. Journal of Nuclear Medicine, 2017, 58, 9-10.	2.8	14
110	Detection Efficacy of ¹⁸Fâ€rhPSMAâ€7.3 PET/CT and Impact on Management in Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Before Potential Salvage Treatment. Journal of Nuclear Medicine, 2021, 62, 1719-1726.	2.8	14
111	Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol. BMC Cancer, 2021, 21, 512.	1.1	14
112	Safety of PSMA-Targeted Molecular Radioligand Therapy with ¹⁷⁷Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312). Journal of Nuclear Medicine, 2021, 62, 1447-1456.	2.8	14
113	68 Ga-labeled Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Imaging: The New Kid on the Blockâ€"Early or Too Early to Draw Conclusions?. European Urology, 2016, 70, 938-940.	0.9	13
114	Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [68Ga]PSMA-PET-guided metastasis-directed therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2328-2338.	3.3	13
115	Pretherapeutic Comparative Dosimetry of ¹⁷⁷Lu-rhPSMA-7.3 and ¹⁷⁷Lu-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine, 2022, 63, 833-839.	2.8	13
116	PSMA-PET for Lymph Node Detection in Recurrent Prostate Cancer: How do we use the Magic Bullet?. Theranostics, 2017, 7, 2046-2047.	4.6	12
117	PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy. EJNMMI Research, 2021, 11, 76.	1.1	12
118	Technical Note: Optimal sampling schedules for kidney dosimetry based on the hybrid planar/SPECT method in 177 Luâ€PSMA therapy. Medical Physics, 2019, 46, 5861-5866.	1.6	11
119	Combining 68Ga-PSMA-PET/CT-Directed and Elective Radiation Therapy Improves Outcome in Oligorecurrent Prostate Cancer: A Retrospective Multicenter Study. Frontiers in Oncology, 2021, 11, 640467.	1.3	11
120	[18F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma. EJNMMI Research, 2021, 11, 70.	1.1	11
121	Evaluation of SUV normalized by lean body mass (SUL) in 68Ga-PSMA11 PET/CT: a bi-centric analysis. EJNMMI Research, 2019, 9, 103.	1.1	11
122	RESIST-PC phase 2 trial: 177Lu-PSMA-617 radionuclide therapy for metastatic castrate-resistant prostate cancer.. Journal of Clinical Oncology, 2019, 37, 5028-5028.	0.8	11
123	Positronâ€emission tomography imaging in urological oncology: Current aspects and developments. International Journal of Urology, 2018, 25, 912-921.	0.5	10
124	Diagnostic performance of quantitative and qualitative parameters for the diagnosis of aortic graft infection using [18F]-FDG PET/CT. Journal of Nuclear Cardiology, 2021, 28, 2220-2228.	1.4	10
125	Important pharmacokinetic parameters for individualization of ¹⁷⁷Luâ€PSMA therapy: A global sensitivity analysis for a physiologicallyâ€based pharmacokinetic model. Medical Physics, 2021, 48, 556-568.	1.6	10
126	A population-based method to determine the time-integrated activity in molecular radiotherapy. EJNMMI Physics, 2021, 8, 82.	1.3	10

#	Article	IF	Citations
127	The sodium iodide symporter (NIS) as theranostic gene: its emerging role in new imaging modalities and non-viral gene therapy. EJNMMI Research, 2022, 12, 25.	1.1	10
128	[11C]Choline PET/CT in therapy response assessment of a neoadjuvant therapy in locally advanced and high risk prostate cancer before radical prostatectomy. Oncotarget, 2016, 7, 63747-63757.	0.8	9
129	Fully integrated whole-body [¹⁸F]-fludeoxyglucose positron emission tomography/magnetic resonance imaging in therapy monitoring of giant cell arteritis. European Heart Journal, 2016, 37, 576-576.	1.0	9
130	Re: Lars BudÃus, Sami-Ramzi Leyh-Bannurah, Georg Salomon, et al. Initial Experience of 68Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. Eur Urol 2016;69:393â€“6. European Urology, 2016, 70, e37-e38.	0.9	9
131	Pitfalls in Ga-68-PSMA-PET/CT: incidental finding of parathyroid adenoma. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1041-1041.	3.3	9
132	Feasibility and Outcome of PSMA-PET-Based Dose-Escalated Salvage Radiotherapy Versus Conventional Salvage Radiotherapy for Patients With Recurrent Prostate Cancer. Frontiers in Oncology, 2021, 11, 715020.	1.3	9
133	Multimodal imaging for radiation therapy planning in patients with primary prostate cancer. Physics and Imaging in Radiation Oncology, 2018, 8, 8-16.	1.2	8
134	Gallium-68 HBED-CC-PSMA Positron Emission Tomography/Magnetic Resonance Imaging for Prostate Fusion Biopsy. Clinical Genitourinary Cancer, 2018, 16, 245-247.	0.9	8
135	Almost 10Âyears of PET/MR attenuation correction: the effect on lesion quantification with PSMA: clinical evaluation on 200 prostate cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 543-553.	3.3	8
136	Is Hypoxia a Factor Influencing PSMA-Directed Radioligand Therapy?â€”An In Silico Study on the Role of Chronic Hypoxia in Prostate Cancer. Cancers, 2021, 13, 3429.	1.7	8
137	Prospective head-to-head comparison of 18F-fluciclovine and 68Ga-PSMA-11 PET/CT for localization of prostate cancer biochemical recurrence after primary prostatectomy.. Journal of Clinical Oncology, 2019, 37, 15-15.	0.8	8
138	Validation of¹⁸F-rhPSMA-7 and¹⁸F-rhPSMA-7.3 PET Imaging Results with Histopathology from Salvage Surgery in Patients with Biochemical Recurrence of Prostate Cancer. Journal of Nuclear Medicine, 2022, 63, 1809-1814.	2.8	8
139	Hyperkalemia in patients treated with endoradiotherapy combined with amino acid infusion is associated with severe metabolic acidosis. EJNMMI Research, 2018, 8, 17.	1.1	6
140	Practice changing for prostate cancer: a vision of the future. Nature Reviews Urology, 2019, 16, 71-72.	1.9	6
141	Cytoreductive radical prostatectomy after chemohormonal therapy in patients with primary metastatic prostate cancer. Asian Journal of Urology, 2022, 9, 69-74.	0.5	6
142	Accuracy of 68Ga-PSMA11 PET/CT on recurrent prostate cancer: Preliminary results from a phase 2/3 prospective trial.. Journal of Clinical Oncology, 2018, 36, 5001-5001.	0.8	6
143	Narrative review: prostate-specific membrane antigen-radioligand therapy in metastatic castration-resistant prostate cancer. Translational Andrology and Urology, 2021, 10, 3963-3971.	0.6	6
144	Exceptional 4-year response to 177Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2212-2213.	3.3	5

#	Article	IF	Citations
145	Positive predictive value and correct detection rate of ¹⁸F-rhPSMA-7 PET in biochemically recurrent prostate cancer validated by composite reference standard. Journal of Nuclear Medicine, 2021, 62, jnumed.120.255661.	2.8	5
146	First Experience Using ¹⁸F-Flubrobenguane PET Imaging in Patients with Suspected Pheochromocytoma or Paraganglioma. Journal of Nuclear Medicine, 2021, 62, 479-485.	2.8	5
147	Nuclear Medicine beyond VISION. Journal of Nuclear Medicine, 2021, 62, jnumed.121.262441.	2.8	5
148	Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using ¹⁷⁷Lu-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH).. Journal of Clinical Oncology, 2021, 39, TPS5087-TPS5087.	0.8	5
149	The Influence of Specific Activity on the Biodistribution of 18F-rhPSMA-7.3: A Retrospective Analysis of Clinical Positron Emission Tomography Data. Journal of Nuclear Medicine, 2021, , jnumed.121.262471.	2.8	5
150	Pre-test 68Ga-PSMA-ligand PET/CT positivity in early biochemical recurrent prostate cancer after radical prostatectomyâ€"validation of a prediction model. EJNMMI Research, 2020, 10, 6.	1.1	5
151	Temporary reactive response of axillary lymph nodes to COVID-19 vaccination on ¹⁸F-rhPSMA-7.3 PET/CT in patients with prostate cancer. Journal of Nuclear Medicine, 2022, , jnumed.121.263758.	2.8	5
152	PSMA PET tumor-to-salivary glands ratio (PSG score) to predict response to Lu-177 PSMA radioligand therapy: An international multicenter retrospective study.. Journal of Clinical Oncology, 2022, 40, 5043-5043.	0.8	5
153	What is the best PET target for early biochemical recurrence of prostate cancer?â€"Authorsâ€™ reply. Lancet Oncology, The, 2019, 20, e609-e610.	5.1	4
154	Double-strand breaks in lymphocyte DNA of humans exposed to [18F]fluorodeoxyglucose and the static magnetic field in PET/MRI. EJNMMI Research, 2020, 10, 43.	1.1	4
155	Initial evaluation of [18F]-FACBC for PET imaging of multiple myeloma. EJNMMI Research, 2022, 12, 4.	1.1	4
156	Preclinical biodistribution and dosimetry and human biodistribution comparing 18F-rhPSMA-7 and single isomer 18F-rhPSMA-7.3. EJNMMI Research, 2022, 12, 8.	1.1	4
157	Diagnosis and Treatment of Prostate Cancer: What Americans Can Learn From International Oncologists. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 344-357.	1.8	3
158	Incidental Finding of Colon Carcinoma Related to High Uptake in 18F-PSMA-1007 PET. Clinical Nuclear Medicine, 2020, 45, 561-562.	0.7	3
159	Multiparametric 18Fâ€"FDG PET/MR follow-up in a patient with autoimmune pancreatitis. European Journal of Hybrid Imaging, 2017, 1, 11.	0.6	2
160	Interim PSMA PET/CT for response evaluation during LuPSMA treatment in mCRPC (INTERIM PET): An explorative, multicenter study.. Journal of Clinical Oncology, 2021, 39, 5066-5066.	0.8	2
161	Value of PET imaging for radiation therapy. Nuklearmedizin - NuclearMedicine, 2021, 60, 326-343.	0.3	2
162	Impact of 68Ga-PSMA-11 PET on the management of biochemically recurrent prostate cancer in a prospective single-arm clinical trial.. Journal of Clinical Oncology, 2020, 38, 292-292.	0.8	2

#	Article	IF	Citations
163	¹⁸F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Curative-Intent Radiation Therapy: A Bicentric Retrospective Study. Journal of Nuclear Medicine, 2022, 63, 1208-1214.	2.8	2
164	Safety and survival outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177â€“prostate-specific membrane antigen (¹⁷⁷Lu-PSMA) after radium-223 (²²³Ra): Interim analysis of the RALU study.. Journal of Clinical Oncology, 2022, 40, 5040-5040.	0.8	2
165	A rare case of polyostotic fibrous dysplasia detected on 18F-rhPSMA-7 PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2927-2929.	3.3	1
166	Clinical experience with 100 consecutive patients treated with Lu-177-labeled PSMA-I&T radioligand therapy for metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2018, 36, 206-206.	0.8	1
167	An in silico study on the effect of the radionuclide half-life on PET/CT imaging with PSMA-targeting radioligands. Nuklearmedizin - NuclearMedicine, 2021, 60, 33-37.	0.3	1
168	Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP): An international multicenter study.. Journal of Clinical Oncology, 2022, 40, 42-42.	0.8	1
169	Tumor Sink effect: Myth or Reality?. Journal of Nuclear Medicine, 2022, , jnumed.122.264119.	2.8	1
170	A PET for All Seasons: 18 F-Fluorodeoxyglucose to Characterize Inflammation and Malignancy in Retroperitoneal Fibrosis?. European Urology, 2017, 71, 934-935.	0.9	0
171	Multimodal therapy in oligometastatic prostate cancer: A glimpse into the future?. Asian Journal of Urology, 2021, 8, 248-250.	0.5	0
172	A survey among German-speaking radiation oncologists on PET-based radiotherapy of prostate cancer. Radiation Oncology, 2021, 16, 82.	1.2	0
173	PSMA-targeted imaging of prostate cancer: evolution of a success story. Asian Journal of Andrology, 2017, 19, 388.	0.8	0
174	Oncological and postoperative outcome of salvage PSMA-radioguided surgery in recurrent prostate cancer.. Journal of Clinical Oncology, 2018, 36, 270-270.	0.8	0
175	Prospective head-to-head comparative phase 3 study between ¹⁸F-fluciclovine and ⁶⁸Ga-PSMA-11 PET/CT in patients with early biochemical recurrence of prostate cancer.. Journal of Clinical Oncology, 2019, 37, 5014-5014.	0.8	0
176	Reply by Authors. Journal of Urology, 2019, 202, 1181-1181.	0.2	0
177	Impact of 68Ga-PSMA-11 PET/CT on staging and management of prostate cancer patients in various clinical settings.. Journal of Clinical Oncology, 2020, 38, 26-26.	0.8	0
178	Cohort study of oligorecurrent prostate cancer patients: Oncological outcomes of patients treated with salvage lymph node dissection via PSMA radioguided surgery.. Journal of Clinical Oncology, 2022, 40, 106-106.	0.8	0
179	Cohort study of patients with oligorecurrent prostate cancer: Oncological outcomes of patients treated with salvage lymph node dissection via PSMA radioguided surgery.. Journal of Clinical Oncology, 2022, 40, 5009-5009.	0.8	0